tiprankstipranks
Trending News
More News >
Getinge AB (GNGBY)
OTHER OTC:GNGBY
Advertisement

Getinge AB (GNGBY) Price & Analysis

Compare
13 Followers

GNGBY Stock Chart & Stats


Getinge AB News

GNGBY FAQ

What was Getinge AB’s price range in the past 12 months?
Getinge AB lowest stock price was $14.99 and its highest was $22.77 in the past 12 months.
    What is Getinge AB’s market cap?
    Getinge AB’s market cap is $5.62B.
      When is Getinge AB’s upcoming earnings report date?
      Getinge AB’s upcoming earnings report date is Oct 21, 2025 which is in 72 days.
        How were Getinge AB’s earnings last quarter?
        Getinge AB released its earnings results on Jul 18, 2025. The company reported $0.199 earnings per share for the quarter, beating the consensus estimate of N/A by $0.199.
          Is Getinge AB overvalued?
          According to Wall Street analysts Getinge AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Getinge AB pay dividends?
            Getinge AB pays a Annually dividend of $0.049 which represents an annual dividend yield of 0.24%. See more information on Getinge AB dividends here
              What is Getinge AB’s EPS estimate?
              Getinge AB’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Getinge AB have?
              Getinge AB has 254,152,370 shares outstanding.
                What happened to Getinge AB’s price movement after its last earnings report?
                Getinge AB reported an EPS of $0.199 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.113%.
                  Which hedge fund is a major shareholder of Getinge AB?
                  Currently, no hedge funds are holding shares in GNGBY

                  Company Description

                  Getinge AB

                  Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems; practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, axius blower mister and coronary shunts, proximal seal systems, ceiling supply units, connected solutions, cleaning and disinfection products, packaging and sealing solutions, monitors and indicators, and SteriTec products. The company also provides thoracic catheters, dry seal chest drain, mobile dry seal drain, dry and wet suction water seal chest drain, and chest drain valves; transitional accessories; endoscope reprocessing; endoscopic vessel harvesting systems; endovascular products; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packing products; intra-aortic balloon counter pulsation therapies; mechanical ventilation products; medical furniture; modular room systems; operating lights and tables; OR integration and management; patient flow management; patient transport; sterile supply management; sterilization; surgical assist systems; surgical perfusion; transport & storage; trays & baskets; and vascular and cardiothoracic surgery solutions. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.

                  Getinge AB (GNGBY) Earnings & Revenues

                  GNGBY Company Deck

                  GNGBY Earnings Call

                  Q2 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call highlights strong organic growth and margin improvements, successful product launches, and a solid financial position. However, significant challenges from tariffs, currency fluctuations, and geopolitical uncertainties are noted. Despite these headwinds, the company remains optimistic about its growth outlook.View all GNGBY earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Dexcom
                  Edwards Lifesciences
                  Koninklijke Philips
                  Steris
                  Zimmer Biomet Holdings

                  Ownership Overview

                  0.03%99.97%
                  Insiders
                  Mutual Funds
                  0.03% Other Institutional Investors
                  99.97% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis